Research

The Chase Family Movement Disorders Center offers opportunities for active participation in cutting edge research in the field through clinical trials.

These studies are conducted in collaboration with other movement disorders specialists throughout North America and Europe. We have several ongoing clinical research studies as noted below, and all patients have the option to participate in one or more clinical trials.

We are also involved in mentoring students and physicians-in-training who will serve the community in the future as neurologists, researchers, or in primary care. 

Clinical Trials

The Chase Family Movement Disorders Center continues to seek new ways to slow the progression of neurodegenerative disorders through clinical trials in collaboration with other movement disorders specialists throughout North America.

We have several ongoing clinical research studies as noted below, and all patients have the option to participate in one or more clinical trials. We are also involved in mentoring physicians-in-training who will serve the community in the future as neurologists or in primary care.

1. Protocol No: TOZ-CLO5 (Sponsor/FDA closed, subjects in f/u) A phase 3, multicenter, randomized, double-blind, placebo-controlled study with an open-label phase to determine the efficacy and safety of tozadenant as adjunctive therapy in levodopa-treated patients with Parkinson’s disease experiencing end of dose wearing-off.

2. Protocol No: 16306A (actively enrolling) RESTORE: A clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess Sustained effects of droxidopa therapy.

3. Protocol No:  ADS-AMT-PD302 (Completed) An open-label safety study of ADS-5102 (amantadine HCl) extended release capsules for the treatment of levodopa induced dyskinesia. Phase 3 study taking place in 90 sites worldwide. This is the open label extension of the double blind study we conducted.

4. Protocol No: IN 11 004 (enrolling) A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study comparing the efficacy and safety of gastric retentive, controlled release Accordian pill™ carbidopa/levodopa (AP CD/LD) to immediate release CD/LD in fluctuating Parkinson's disease patients.

5. Protocol No: IN 11 004 OLE (roll-over) An open-label, multicenter follow-up study designed to evaluate long term effects of Accordian pill™ carbidopa/levodopa (AP CD/LD) in fluctuating Parkinson's disease patients who completed study in 11 004. This is the open label extension to the above mentioned study.

6. Protocol No: INO-PD-P3-2014 (enrolling) A randomized, double-blind, placebo-controlled trial of urate elevating Inosine treatment to slow clinical decline in early Parkinson’s disease (PD). Abbreviated study name: SURE-PD3 (Study of URate Elevation in PD, phase 3).

7. Protocol No: Eli Lilly 17S-MC-HBEH (pending Jan. 2018) The Effect of LY3154207  on Cognition in Mild-to-Moderate Parkinson’s Disease Dementia (PDD).

8. Protocol No: P2B001/003 (pending Jan. 2018) A Phase 3, 12 week, multi-center, multinational, Randomized, Double Blind, Double Dummy, Parallel Group Study to determine the Efficacy, Safety, and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects with Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.